- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07950852
Mirogabalin vs. Melatonin for Pain and Anxiety After Total Knee Arthroplasty Under Spinal Anesthesia
Mirogabalin Versus Melatonin for Perioperative Anxiolysis and Opioid-Sparing Analgesia After Total Knee Arthroplasty Under Spinal Anesthesia: A Double-Blind, Randomized, Placebo-Controlled Trial
Total knee arthroplasty (TKA) is frequently associated with moderate-to-severe postoperative pain, substantial opioid consumption, and preoperative anxiety. Although spinal anesthesia is preferred for TKA, it does not provide prolonged analgesia after the block resolves.
This prospective, randomized, double-blind, placebo-controlled trial aims to evaluate and compare the efficacy of perioperative oral mirogabalin versus melatonin versus placebo as opioid-sparing analgesic adjuncts in patients undergoing elective unilateral TKA under spinal anesthesia. The primary objective is to assess their impact on postoperative pain intensity and perioperative anxiety levels.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Preoperative anxiety affects 30% to 70% of patients undergoing total knee arthroplasty (TKA) and can exacerbate postoperative pain, increase opioid consumption, and delay recovery. Multimodal perioperative optimization within Enhanced Recovery After Surgery (ERAS) protocols is essential to address these challenges.
Mirogabalin is a novel, selective ligand of the α₂δ subunit of voltage-gated calcium channels with a long dissociation half-life, demonstrating analgesic and anxiolytic properties. Melatonin is an endogenous pineal hormone with well-characterized chronobiotic, sedative, anxiolytic, and antinociceptive actions. Despite their potential, no randomized controlled trial has directly compared mirogabalin and melatonin for perioperative optimization in TKA under spinal anesthesia.
Eligible consenting participants (aged 50-70 years, ASA I-III, scheduled for primary elective unilateral TKA under spinal anesthesia) will be randomized (1:1:1) to one of three parallel groups:
- Mirogabalin Group: Oral mirogabalin administered at 10:00 PM the night before surgery, 1 hour before spinal anesthesia, 10:00 PM on surgery day, and at 10:00 AM and 10:00 PM on Postoperative Day 1.
- Melatonin Group: Oral melatonin administered at 10:00 PM the night before surgery, 1 hour before spinal anesthesia, and 10:00 PM on surgery day; matching placebo at 10:00 AM on Postoperative Day 1, followed by melatonin at 10:00 PM on Postoperative Day 1.
- Placebo Group: Matching placebo administered at identical time points.
All patients will receive standardized intraoperative spinal anesthesia (hyperbaric bupivacaine + fentanyl) and standardized background multimodal analgesia (paracetamol, ketorolac, and intraoperative dexamethasone).
Outcomes assessed up to 48 hours postoperatively include Numeric Rating Scale (NRS) pain scores, Amsterdam Preoperative Anxiety and Information Scale (APAIS) scores, 24-hour and 48-hour cumulative opioid (nalbuphine) consumption, time to first rescue analgesia, sedation level (MOOA/S), sleep quality (SQS), time to first mobilization, hemodynamic stability, and adverse events.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Kerollos Moneer Neseem Mikhael, MD
- Numéro de téléphone: 00201288549959
- E-mail: Kmnmk87@med.bsu.edu.eg
Lieux d'étude
-
-
-
Banī Suwayf, Egypte
- Beni-Suef University Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 50 to 70 years.
- American Society of Anesthesiologists (ASA) physical status I, II, or III.
- Scheduled for elective primary unilateral total knee arthroplasty (TKA) under spinal anesthesia.
- Body Mass Index (BMI) between 18.5 and 35 kg/m².
- Able to understand and complete study questionnaires (APAIS, NRS) in the local language.
- Provision of signed written informed consent.
Exclusion Criteria:
- Contraindication to spinal anesthesia (e.g., coagulopathy, local puncture site infection, severe spinal deformity, or patient refusal).
- Known hypersensitivity or allergy to mirogabalin, melatonin, gabapentinoids, or study medication excipients.
- Pre-existing chronic pain syndrome requiring long-term opioid, gabapentinoid, or melatonin therapy.
- Severe renal impairment (estimated glomerular filtration rate < 30 mL/min/1.73 m²) or end-stage renal disease.
- Severe hepatic impairment (Child-Pugh class C).
- Psychiatric illness impairing comprehension or cooperation (e.g., dementia, active psychosis) or current treatment with anxiolytics, antipsychotics, or antidepressants.
- Current pregnancy or breastfeeding.
- Revision arthroplasty, bilateral TKA procedures, or intraoperative conversion to general anesthesia.
- Known sleep disorder under active pharmacological treatment, or current shift-work disorder.
- Participation in another interventional drug trial within 30 days prior to enrollment.
- Inability to complete visual/numeric pain and anxiety scales due to visual, cognitive, or language barriers.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Group G (Mirogabalin)
Patients receive oral mirogabalin 10 mg at 10:00 PM on the night before surgery, 1 hour before planned spinal anesthesia, 10:00 PM on the day of surgery, and at 10:00 AM and 10:00 PM on the first postoperative day (Postoperative Day 1). All participants receive standardized spinal anesthesia (hyperbaric bupivacaine 0.5% + fentanyl 25 mcg) and multimodal background analgesia (paracetamol 1 g IV q6h, ketorolac 30 mg IV q12h, and intraoperative dexamethasone 8 mg IV). |
Oral mirogabalin 10 mg tablet administered per protocol schedule (5 total doses perioperatively). |
|
Comparateur actif: Group M (Melatonin)
Patients receive oral melatonin 10 mg at 10:00 PM on the night before surgery, 1 hour before planned spinal anesthesia, and 10:00 PM on the day of surgery. On Postoperative Day 1, patients receive a matching placebo tablet at 10:00 AM (to preserve blinding), followed by melatonin 10 mg at 10:00 PM. All participants receive standardized spinal anesthesia and identical background multimodal analgesia. |
Oral melatonin 10 mg tablet administered per protocol schedule (4 active doses + 1 placebo dose at 10:00 AM POD 1). |
|
Comparateur placebo: Group P (Placebo)
Patients receive matching oral placebo tablets administered at corresponding time points: 10:00 PM the night before surgery, 1 hour before planned spinal anesthesia, 10:00 PM on the day of surgery, and at 10:00 AM and 10:00 PM on Postoperative Day 1. All participants receive standardized spinal anesthesia and identical background multimodal analgesia. |
Matching inert oral placebo tablet administered to Group P (5 total doses) and Group M (1 dose at 10:00 AM POD 1). |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Postoperative Pain Intensity Scores
Délai: Assessed at 2, 12, 24, and 48 hours postoperatively.
|
Assessed using the Numeric Rating Scale (NRS), where scores range from 0 to 10 (0 = "no pain", 10 = "worst possible pain"). Lower scores represent a more favorable clinical outcome (less pain intensity), whereas higher scores represent an unfavorable outcome. |
Assessed at 2, 12, 24, and 48 hours postoperatively.
|
|
Perioperative Anxiety Scores
Délai: Preoperatively (holding area, 60-120 minutes before spinal anesthesia), and postoperatively at 2 and 12 hours.
|
Assessed using the anxiety subscale of the Amsterdam Preoperative Anxiety and Information Scale (APAIS). The anxiety subscale consists of 4 items rated on a 5-point Likert scale (1 = not at all, 5 = extremely), with total anxiety scores ranging from 4 to 20. Lower scores represent a more favorable clinical outcome (lower anxiety), whereas higher scores represent an unfavorable outcome. |
Preoperatively (holding area, 60-120 minutes before spinal anesthesia), and postoperatively at 2 and 12 hours.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Total Cumulative Postoperative Opioid Consumption
Délai: First 24 and 48 hours postoperatively.
|
Total intravenous nalbuphine consumption measured in milligrams (mg) administered as rescue analgesia during the first 24 and 48 postoperative hours. Lower cumulative dose values represent a more favorable outcome (greater opioid-sparing effect). |
First 24 and 48 hours postoperatively.
|
|
Time to First Request for Rescue Analgesia
Délai: Up to 48 hours postoperatively.
|
Time elapsed (in minutes) from arrival in the Post-Anesthesia Care Unit (PACU, time zero) to the first administration of rescue IV nalbuphine for NRS pain score >= 4. Longer duration (higher values in minutes) represents a more favorable outcome (prolonged postoperative analgesia). |
Up to 48 hours postoperatively.
|
|
Postoperative Sedation Scores
Délai: Assessed at 2, 12, 24, and 48 hours postoperatively.
|
Evaluated using the Modified Observer's Assessment of Alertness/Sedation (MOOA/S) scale, ranging from 0 (does not respond to deep algic stimulus) to 5 (responds readily to name spoken in normal tone). A score of 5 represents alertness (favorable recovery state), whereas lower scores indicate deeper sedation (unfavorable/excessive drug-induced sedation). |
Assessed at 2, 12, 24, and 48 hours postoperatively.
|
|
Incidence of Postoperative Nausea and Vomiting and Requirement for Rescue Antiemetics
Délai: Assessed at 2, 12, 24, and 48 hours postoperatively.
|
Number of participants experiencing nausea or vomiting and requiring rescue antiemetic therapy. A lower incidence (fewer participants affected) represents a favorable outcome. |
Assessed at 2, 12, 24, and 48 hours postoperatively.
|
|
Postoperative Sleep Quality Score
Délai: Assessed at 48 hours postoperatively.
|
Assessed using the Single-Item Sleep Quality Scale (SQS), where overall sleep quality over the 48-hour postoperative period is rated on a 0 to 10 scale (0 = terrible, 10 = excellent). Higher scores represent a more favorable outcome (better sleep quality). |
Assessed at 48 hours postoperatively.
|
|
Time to First Postoperative Mobilization
Délai: Up to 48 hours postoperatively.
|
Time elapsed (in hours) from arrival in the PACU to first achieving bedside sitting and subsequent assisted ambulation. Shorter duration (lower values in hours) represents a more favorable recovery outcome. |
Up to 48 hours postoperatively.
|
|
Incidence of Treatment-Emergent Adverse Events
Délai: Up to 48 hours postoperatively.
|
Number of participants experiencing adverse drug events, including dizziness, excessive somnolence, headache, pruritus, constipation, and urinary retention. A lower incidence represents a more favorable safety profile. |
Up to 48 hours postoperatively.
|
|
Incidence of Intraoperative Hypotension and Bradycardia
Délai: Intraoperatively (from spinal injection to completion of surgery).
|
Number of participants experiencing spinal-anesthesia-related hypotension (mean arterial pressure drop > 20% from baseline requiring IV fluids/ephedrine) or bradycardia (heart rate < 50 bpm requiring IV atropine). A lower incidence represents a more favorable hemodynamic stability profile. |
Intraoperatively (from spinal injection to completion of surgery).
|
|
Patient Satisfaction With Perioperative Analgesia
Délai: Assessed at 24 hours postoperatively.
|
Evaluated on a 5-point Likert scale (1 = very dissatisfied, 5 = very satisfied). Higher scores represent a more favorable outcome. |
Assessed at 24 hours postoperatively.
|
|
Length of Postoperative Hospital Stay
Délai: From completion of surgery (arrival in the PACU) until the date and time of meeting formal hospital discharge criteria, assessed up to 7 days postoperatively.
|
Duration of hospital stay measured in hours from completion of surgery until meeting formal discharge criteria. Shorter stay duration (lower values) represents a more favorable outcome. |
From completion of surgery (arrival in the PACU) until the date and time of meeting formal hospital discharge criteria, assessed up to 7 days postoperatively.
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- La douleur
- Manifestations neurologiques
- Les troubles mentaux
- Complications postopératoires
- Processus pathologiques
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Douleur, Postopératoire
- Troubles anxieux
- Hormones
- Hormones, substituts hormonaux et antagonistes hormonaux
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Indoles
- Tryptamines
- Mélatonine
- mirogabalin
Autres numéros d'identification d'étude
- FMBSUREC/03112026/Mahmoud
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified individual participant data (IPD) underlying the published results (including baseline demographics, intervention group allocation, pain scores, anxiety scores, cumulative opioid consumption, and adverse event data) will be made available to qualified researchers upon reasonable request to the
Délai de partage IPD
Beginning 6 months and ending 3 years following article publication
Critères d'accès au partage IPD
Available to academic researchers who provide a methodologically sound proposal approved by the Beni-Suef University Research Ethics Committee
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .